MacuLogix® equips eye care professionals with the only disease management platform to effectively diagnose, manage and treat patients with age-related macular degeneration (AMD). By leveraging the science of dark adaptation through its AdaptDx® and AdaptDx Pro™ guided by Theia™, MacuLogix is working to eliminate preventable blindness caused by AMD—a chronic, progressive disease that impacts nearly 200 million people worldwide and goes undiagnosed in 25 percent of patients. The company's dark adaptation functional testing technology combined with its MeyePractice™ software creates a powerful disease management platform that incorporates patient, clinical and business management data into one simple dashboard. MacuLogix’s Practice Management Consultants also help eye care professionals maximize their investment to benefit their patients and practice. 

Contact: Steve Fotos
[email protected]